Oxidative Medicine and Cellular Longevity / 2019 / Article / Fig 2

Research Article

Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway

Figure 2

Protein levels of signaling pathways after Myr treatment. (a, b) Myr inhibited the Nrf2/HO-1 pathway; (c, d) Myr inhibited the phosphorylation and nuclei translocation of p65; (d, e) Myr inhibited the phosphorylation of p38 and JNK1.2 MAPK kinase. , versus the CON group or the Myr group, # versus the AB+Myr group.